Odile Boespflug-Tanguy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Odile Boespflug-Tanguy has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Eleonore Eymard-Pierre
Cytogénétique médicale, CHU Estaing , Clermont-Ferrand
3 shared publications - Imen Dorboz
Université de Paris, NeuroDiderot, UMR 1141, INSERM, Paris, France
3 shared publications - Monique Elmaleh-Bergès
Radiology Department AP‐HP, Robert‐Debré University Hospital Paris France
3 shared publications - Catherine Vaurs-Barrière
Genetics, Reproduction and Development Institute (iGReD), CNRS, INSERM, Clermont Auvergne University, Clermont-Ferrand, France
2 shared publications - Davide Tonduti
COALA (Center for Diagnosis and Treatment of Leukodystrophies and Genetic Leukoencephalopathies), Unit of Pediatric Neurology, Vittore Buzzi Children's Hospital, Milan, Italy; Neuroscience Research Center, Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, Milan, Italy
2 shared publications - Enrico Bertini
Unit of Muscular and Neurodegenerative Diseases Bambino Gesù Children's Hospital, IRCCS Rome Italy
2 shared publications
Latest Publications
- 7 April 2017
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 48 (03) , 205-206
Lack of Long-Term Neurologic Efficacy of Zileuton in Sjögren–Larsson's Syndrome
Sjögren-Larsson's syndrome (SLS) is a rare and disabling genetic disorder characterized by congenital pruritic ichthyosis, mental retardation, and progressive spastic diplegia. Disease course often features retinal crystalline inclusions on the eye fundus. Cerebral MRI (magnetic resonance imaging) shows dysmyelination. Proton magnetic resonance spectroscopy (1H-MRS)[1] shows pathognomonic abnormal lipid peaks at 1.3 and 0.9 ppm in white matter (WM). SLS is caused by a deficiency of fatty aldehyde dehydrogenase (FALDH), a microsomal enzyme of lipid metabolism, leading to accumulation of long-chain fatty alcohols, branched-chain alcohols, and leukotriene B4 (LTB4) in skin, retina, and WM of the central nervous system (CNS). SLS is confirmed by low FALDH activity in cultured skin fibroblasts and/or analysis of the ALDH3A2 gene encoding FALDH.[1] More than 15 years ago, a therapeutic approach using zileuton, a 5-lipoxygenase inhibitor that blocks the synthesis of LTB4, was reported as helpful on pruritus and behavior in three of five patients with SLS in an open-label trial according to two papers from Willemsen et al.[2] [3] More recently, a double-blind placebo-controlled crossover study in 10 patients over a 16-week period showed improvement of pruritus in only one patient without efficacy on ichthyosis or neurologic symptoms.[4] Willemsen et al also reported that zileuton decreased LTB4 levels in urine at 5 weeks of treatment in one child[2] and at 3 months of treatment in five adults and adolescents.[3] Three patients had a decreasing lipid peak at 1.3 ppm on 1H-MRS.[2] [3] No long-term follow-up of patients with SLS treated by zileuton has been published to date, and the effects of zileuton in children younger than 5 years remain unknown. We used zileuton to treat seven unrelated children (six females and one male) aged between 17 months and 16 years (median age: 4 years) with typical SLS confirmed by low FALDH activity and/or ALDH3A2 analysis ([Table 1]). Dose was between 40 and 100 mg/kg/day, divided into three or four times (maximal dose: 3,600 mg/day). The French Drug Safety Agency approved the use of zileuton for SLS, and informed parental consent was obtained for all patients. Dermatological (ichthyosis and pruritus), neurologic (spasticity, language, and cognition), and ophthalmological signs were evaluated yearly. Cerebral MRI and 1H-MRS were performed before and every 2 years during treatment. Serum aminotransferase levels were controlled monthly during the first 6 months of treatment. Zileuton was discontinued after 8 months in a 16-year-old girl due to a fourfold increase in serum aminotransferases. The six remaining patients were treated during a median time of 3.5 years (range: 6 months to 10 years) without side effects including normal serum aminotransferase levels. No improvement in ichthyosis, pruritus, photophobia, language, and visual or motor abilities was reported. No change in eye fundus was found. The family of a 4-year-old child given 5 years of treatment described progress in attention and executive functions, but successive neuropsychological evaluations failed to manifest this finding. Cerebral MRI before and during treatment showed various degrees of abnormal WM signals with no improvement over time. MRI follow-up found cortical atrophy appearing in frontal regions in one patient and a worsening of dysmyelination in another patient. 1H-MRS showed persistent lipid peaks at various time points, with no change in other metabolic peaks. Zileuton inhibits cysteinyl LT and LTB4 synthesis. It may be helpful in SLS by limiting the in-tissue accumulation of LTB4 and ω-hydroxy LTB4 metabolites caused by FALDH deficiency.[1] Zileuton may also limit systemic effects of LTB4, such as pruritus. It was hoped that zileuton would bring neurologic improvement, without evidence of the role of LTB4 in SLS-associated motor and cognitive impairment.[1] [3] This is the first paper to report long-term follow-up of zileuton in children and adolescents with SLS. We observed neither improvement nor stabilization in motor capacities. Spastic paraplegia progressed in all cases. Improvement in attention capacities was observed in one of the youngest patients treated, but this improvement could be related to maturation of the CNS. It is difficult to assess whether zileuton was directly involved in this effect, especially as cerebral 1H-MRS found no change in lipid peaks, contrary to the first three patients reported by Willemsen et al.[2] [3] after 1 to 3 months of treatment. Urinary LTB4 levels, which can reflect zileuton intake, were not available in our series of patients, but adherence to treatment was satisfactory in all cases. LTB4 and ω-hydroxy-LTB4 levels were reported as decreased with a daily dose of 40 mg/kg of zileuton[1] [2] in the initial studies but could not be technically assessed in the more recent study.[4] The dose used here was identical or even lower. Our long-term follow-up data demonstrates no apparent neurologic effects of zileuton in SLS over time, not just in adolescents but also younger children. Effects on dermatological symptoms may differ among patients. Fuijkschot et al advocated discontinuing zileuton if no cutaneous effect was observed after a few weeks of treatment.[4] In a recent review on therapeutic approaches in SLS, Rizzo suggested an alternative approach to pharmacological inhibition of LTB4 receptors using small bioactive molecules that may be more fruitful than zileuton.[5]
- 7 April 2017
- Published by Georg Thieme Verlag KG in Neuropediatrics
- Vol. 48 (03) , 205-206
Lack of Long-Term Neurologic Efficacy of Zileuton in Sjögren–Larsson's Syndrome
Sjögren-Larsson's syndrome (SLS) is a rare and disabling genetic disorder characterized by congenital pruritic ichthyosis, mental retardation, and progressive spastic diplegia. Disease course often features retinal crystalline inclusions on the eye fundus. Cerebral MRI (magnetic resonance imaging) shows dysmyelination. Proton magnetic resonance spectroscopy (1H-MRS)[1] shows pathognomonic abnormal lipid peaks at 1.3 and 0.9 ppm in white matter (WM). SLS is caused by a deficiency of fatty aldehyde dehydrogenase (FALDH), a microsomal enzyme of lipid metabolism, leading to accumulation of long-chain fatty alcohols, branched-chain alcohols, and leukotriene B4 (LTB4) in skin, retina, and WM of the central nervous system (CNS). SLS is confirmed by low FALDH activity in cultured skin fibroblasts and/or analysis of the ALDH3A2 gene encoding FALDH.[1] More than 15 years ago, a therapeutic approach using zileuton, a 5-lipoxygenase inhibitor that blocks the synthesis of LTB4, was reported as helpful on pruritus and behavior in three of five patients with SLS in an open-label trial according to two papers from Willemsen et al.[2] [3] More recently, a double-blind placebo-controlled crossover study in 10 patients over a 16-week period showed improvement of pruritus in only one patient without efficacy on ichthyosis or neurologic symptoms.[4] Willemsen et al also reported that zileuton decreased LTB4 levels in urine at 5 weeks of treatment in one child[2] and at 3 months of treatment in five adults and adolescents.[3] Three patients had a decreasing lipid peak at 1.3 ppm on 1H-MRS.[2] [3] No long-term follow-up of patients with SLS treated by zileuton has been published to date, and the effects of zileuton in children younger than 5 years remain unknown. We used zileuton to treat seven unrelated children (six females and one male) aged between 17 months and 16 years (median age: 4 years) with typical SLS confirmed by low FALDH activity and/or ALDH3A2 analysis ([Table 1]). Dose was between 40 and 100 mg/kg/day, divided into three or four times (maximal dose: 3,600 mg/day). The French Drug Safety Agency approved the use of zileuton for SLS, and informed parental consent was obtained for all patients. Dermatological (ichthyosis and pruritus), neurologic (spasticity, language, and cognition), and ophthalmological signs were evaluated yearly. Cerebral MRI and 1H-MRS were performed before and every 2 years during treatment. Serum aminotransferase levels were controlled monthly during the first 6 months of treatment. Zileuton was discontinued after 8 months in a 16-year-old girl due to a fourfold increase in serum aminotransferases. The six remaining patients were treated during a median time of 3.5 years (range: 6 months to 10 years) without side effects including normal serum aminotransferase levels. No improvement in ichthyosis, pruritus, photophobia, language, and visual or motor abilities was reported. No change in eye fundus was found. The family of a 4-year-old child given 5 years of treatment described progress in attention and executive functions, but successive neuropsychological evaluations failed to manifest this finding. Cerebral MRI before and during treatment showed various degrees of abnormal WM signals with no improvement over time. MRI follow-up found cortical atrophy appearing in frontal regions in one patient and a worsening of dysmyelination in another patient. 1H-MRS showed persistent lipid peaks at various time points, with no change in other metabolic peaks. Zileuton inhibits cysteinyl LT and LTB4 synthesis. It may be helpful in SLS by limiting the in-tissue accumulation of LTB4 and ω-hydroxy LTB4 metabolites caused by FALDH deficiency.[1] Zileuton may also limit systemic effects of LTB4, such as pruritus. It was hoped that zileuton would bring neurologic improvement, without evidence of the role of LTB4 in SLS-associated motor and cognitive impairment.[1] [3] This is the first paper to report long-term follow-up of zileuton in children and adolescents with SLS. We observed neither improvement nor stabilization in motor capacities. Spastic paraplegia progressed in all cases. Improvement in attention capacities was observed in one of the youngest patients treated, but this improvement could be related to maturation of the CNS. It is difficult to assess whether zileuton was directly involved in this effect, especially as cerebral 1H-MRS found no change in lipid peaks, contrary to the first three patients reported by Willemsen et al.[2] [3] after 1 to 3 months of treatment. Urinary LTB4 levels, which can reflect zileuton intake, were not available in our series of patients, but adherence to treatment was satisfactory in all cases. LTB4 and ω-hydroxy-LTB4 levels were reported as decreased with a daily dose of 40 mg/kg of zileuton[1] [2] in the initial studies but could not be technically assessed in the more recent study.[4] The dose used here was identical or even lower. Our long-term follow-up data demonstrates no apparent neurologic effects of zileuton in SLS over time, not just in adolescents but also younger children. Effects on dermatological symptoms may differ among patients. Fuijkschot et al advocated discontinuing zileuton if no cutaneous effect was observed after a few weeks of treatment.[4] In a recent review on therapeutic approaches in SLS, Rizzo suggested an alternative approach to pharmacological inhibition of LTB4 receptors using small bioactive molecules that may be more fruitful than zileuton.[5]
- 1 December 2015
- Published by Elsevier in Clinical Biochemistry
- Vol. 48 (18) , 1317-1323
Efficient detection of frequent eIF2B mutations for the rapid molecular diagnosis of CACH/VWM syndrome
- 1 December 2015
- Published by Elsevier in Clinical Biochemistry
- Vol. 48 (18) , 1317-1323
Efficient detection of frequent eIF2B mutations for the rapid molecular diagnosis of CACH/VWM syndrome
- Open Access
- 2 September 2015
- Published by Springer Nature in BMC Medical Genetics
- Vol. 16 (1) , 77
Insertion of an extra copy of Xq22.2 into 1p36 results in functional duplication of the PLP1 gene in a girl with classical Pelizaeus-Merzbacher disease
Pelizaeus-Merzbacher disease (PMD) is an X-linked dysmyelinating disorder characterized by nystagmus, hypotonia, ataxia, progressive spasticity, and cognitive decline. PMD classically results from a duplication of a genomic segment encompassing the entire PLP1 gene. Since the PLP1 gene is located in Xq22, PMD affects mostly boys. Here we report the case of a girl with typical PMD. Copy number analysis of the PLP1 locus revealed a duplication of the entire gene and FISH analysis showed that the extra copy of the PLP1 gene was actually inserted in chromosome 1p36. This insertion of an additional copy of PLP1 in an autosome led to a functional duplication irrespective of the X-inactivation pattern. Subsequent overexpression of PLP1 was the cause of the PMD phenotype observed in this girl. Further sequencing of the breakpoint junction revealed a microhomology and thus suggested a replication based mechanism (such as FoSTeS or MMBIR). This case emphasizes the susceptibility of the PLP1 locus to complex rearrangement likely driven by the Xq22 local genomic architecture. In addition, careful consideration should be given to girls with classical PMD clinical features since they usually experience complex PLP1 genomic alteration with a distinct risk of inheritance.
- 2 September 2015
- Published by Springer Nature in BMC Medical Genetics
- Vol. 16 (1) , 77
Open AccessInsertion of an extra copy of Xq22.2 into 1p36 results in functional duplication of the PLP1 gene in a girl with classical Pelizaeus-Merzbacher disease
Pelizaeus-Merzbacher disease (PMD) is an X-linked dysmyelinating disorder characterized by nystagmus, hypotonia, ataxia, progressive spasticity, and cognitive decline. PMD classically results from a duplication of a genomic segment encompassing the entire PLP1 gene. Since the PLP1 gene is located in Xq22, PMD affects mostly boys. Here we report the case of a girl with typical PMD. Copy number analysis of the PLP1 locus revealed a duplication of the entire gene and FISH analysis showed that the extra copy of the PLP1 gene was actually inserted in chromosome 1p36. This insertion of an additional copy of PLP1 in an autosome led to a functional duplication irrespective of the X-inactivation pattern. Subsequent overexpression of PLP1 was the cause of the PMD phenotype observed in this girl. Further sequencing of the breakpoint junction revealed a microhomology and thus suggested a replication based mechanism (such as FoSTeS or MMBIR). This case emphasizes the susceptibility of the PLP1 locus to complex rearrangement likely driven by the Xq22 local genomic architecture. In addition, careful consideration should be given to girls with classical PMD clinical features since they usually experience complex PLP1 genomic alteration with a distinct risk of inheritance.
- 26 May 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 84 (21) , 2195-2197
Cystic leukoencephalopathy with cortical dysplasia related to LAMB1 mutations
- 26 May 2015
- Published by Wolters Kluwer Health in Neurology
- Vol. 84 (21) , 2195-2197
Cystic leukoencephalopathy with cortical dysplasia related to LAMB1 mutations
- Open Access
- 8 February 2015
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 10 (1) , 13
New spastic paraplegia phenotype associated to mutation of NFU1
Recently an early onset lethal encephalopathy has been described in relation to mutations of NFU1, one of the genes involved in iron-sulfur cluster metabolism. We report a new NFU1 mutated patient presenting with a milder phenotype characterized by a later onset, a slowly progressive spastic paraparesis with relapsing-remitting episodes, mild cognitive impairment and a long survival. The early white matter abnormalities observed on MRI was combined with a mixed sensory-motor neuropathy in the third decade. Our case clearly suggests the importance of considering NFU1 mutation in slowly evolving leukoencephalopathy with high glycine concentration.
- 8 February 2015
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 10 (1) , 13
Open AccessNew spastic paraplegia phenotype associated to mutation of NFU1
Recently an early onset lethal encephalopathy has been described in relation to mutations of NFU1, one of the genes involved in iron-sulfur cluster metabolism. We report a new NFU1 mutated patient presenting with a milder phenotype characterized by a later onset, a slowly progressive spastic paraparesis with relapsing-remitting episodes, mild cognitive impairment and a long survival. The early white matter abnormalities observed on MRI was combined with a mixed sensory-motor neuropathy in the third decade. Our case clearly suggests the importance of considering NFU1 mutation in slowly evolving leukoencephalopathy with high glycine concentration.
- Open Access
- 28 October 2013
- Published by Hindawi Limited in Human Mutation
- Vol. 35 (1) , 149
Analysis ofLMNB1Duplications in Autosomal Dominant Leukodystrophy Provides Insights into Duplication Mechanisms and Allele-Specific Expression
Autosomal dominant leukodystrophy (ADLD) is an adult onset demyelinating disorder that is caused by duplications of the lamin B1 (LMNB1) gene. However, as only a few cases have been analyzed in detail, the mechanisms underlying LMNB1 duplications are unclear. We report the detailed molecular analysis of the largest collection of ADLD families studied, to date. We have identified the minimal duplicated region necessary for the disease, defined all the duplication junctions at the nucleotide level and identified the first inverted LMNB1 duplication. We have demonstrated that the duplications are not recurrent; patients with identical duplications share the same haplotype, likely inherited from a common founder and that the duplications originated from intrachromosomal events. The duplication junction sequences indicated that nonhomologous end joining or replication-based mechanisms such fork stalling and template switching or microhomology-mediated break induced repair are likely to be involved. LMNB1 expression was increased in patients' fibroblasts both at mRNA and protein levels and the three LMNB1 alleles in ADLD patients show equal expression, suggesting that regulatory regions are maintained within the rearranged segment. These results have allowed us to elucidate duplication mechanisms and provide insights into allele-specific LMNB1 expression levels
- 28 October 2013
- Published by Hindawi Limited in Human Mutation
- Vol. 35 (1) , 149
Open AccessAnalysis ofLMNB1Duplications in Autosomal Dominant Leukodystrophy Provides Insights into Duplication Mechanisms and Allele-Specific Expression
Autosomal dominant leukodystrophy (ADLD) is an adult onset demyelinating disorder that is caused by duplications of the lamin B1 (LMNB1) gene. However, as only a few cases have been analyzed in detail, the mechanisms underlying LMNB1 duplications are unclear. We report the detailed molecular analysis of the largest collection of ADLD families studied, to date. We have identified the minimal duplicated region necessary for the disease, defined all the duplication junctions at the nucleotide level and identified the first inverted LMNB1 duplication. We have demonstrated that the duplications are not recurrent; patients with identical duplications share the same haplotype, likely inherited from a common founder and that the duplications originated from intrachromosomal events. The duplication junction sequences indicated that nonhomologous end joining or replication-based mechanisms such fork stalling and template switching or microhomology-mediated break induced repair are likely to be involved. LMNB1 expression was increased in patients' fibroblasts both at mRNA and protein levels and the three LMNB1 alleles in ADLD patients show equal expression, suggesting that regulatory regions are maintained within the rearranged segment. These results have allowed us to elucidate duplication mechanisms and provide insights into allele-specific LMNB1 expression levels
- Open Access
- 16 June 2011
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 6 (1) , 40
Molecular Genetic Analysis of the PLP1 Gene in 38 Families with PLP1-related disorders: Identification and Functional Characterization of 11 Novel PLP1 Mutations
Background: The breadth of the clinical spectrum underlying Pelizaeus-Merzbacher disease and spastic paraplegia type 2 is due to the extensive allelic heterogeneity in the X-linked PLP1 gene encoding myelin proteolipid protein (PLP). PLP1 mutations range from gene duplications of variable size found in 60-70% of patients to intragenic lesions present in 15-20% of patients. Methods: Forty-eight male patients from 38 unrelated families with a PLP1-related disorder were studied. All DNA samples were screened for PLP1 gene duplications using real-time PCR. PLP1 gene sequencing analysis was performed on patients negative for the duplication. The mutational status of all 14 potential carrier mothers of the familial PLP1 gene mutation was determined as well as 15/24 potential carrier mothers of the PLP1 duplication. Results and Conclusions: PLP1 gene duplications were identified in 24 of the unrelated patients whereas a variety of intragenic PLP1 mutations were found in the remaining 14 patients. Of the 14 different intragenic lesions, 11 were novel; these included one nonsense and 7 missense mutations, a 657-bp deletion, a microdeletion and a microduplication. The functional significance of the novel PLP1 missense mutations, all occurring at evolutionarily conserved residues, was analysed by the MutPred tool whereas their potential effect on splicing was ascertained using the Skippy algorithm and a neural network. Although MutPred predicted that all 7 novel missense mutations would be likely to be deleterious, in silico analysis indicated that four of them (p.Leu146Val, p.Leu159Pro, p.Thr230Ile, p.Ala247Asp) might cause exon skipping by altering exonic splicing elements. These predictions were then investigated in vitro for both p.Leu146Val and p.Thr230Ile by means of RNA or minigene studies and were subsequently confirmed in the case of p.Leu146Val. Peripheral neuropathy was noted in four patients harbouring intragenic mutations that altered RNA processing, but was absent from all PLP1-duplication patients. Unprecedentedly, family studies revealed the de novo occurrence of the PLP1 duplication at a frequency of 20%.
- 16 June 2011
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 6 (1) , 40
Open AccessMolecular Genetic Analysis of the PLP1 Gene in 38 Families with PLP1-related disorders: Identification and Functional Characterization of 11 Novel PLP1 Mutations
Background: The breadth of the clinical spectrum underlying Pelizaeus-Merzbacher disease and spastic paraplegia type 2 is due to the extensive allelic heterogeneity in the X-linked PLP1 gene encoding myelin proteolipid protein (PLP). PLP1 mutations range from gene duplications of variable size found in 60-70% of patients to intragenic lesions present in 15-20% of patients. Methods: Forty-eight male patients from 38 unrelated families with a PLP1-related disorder were studied. All DNA samples were screened for PLP1 gene duplications using real-time PCR. PLP1 gene sequencing analysis was performed on patients negative for the duplication. The mutational status of all 14 potential carrier mothers of the familial PLP1 gene mutation was determined as well as 15/24 potential carrier mothers of the PLP1 duplication. Results and Conclusions: PLP1 gene duplications were identified in 24 of the unrelated patients whereas a variety of intragenic PLP1 mutations were found in the remaining 14 patients. Of the 14 different intragenic lesions, 11 were novel; these included one nonsense and 7 missense mutations, a 657-bp deletion, a microdeletion and a microduplication. The functional significance of the novel PLP1 missense mutations, all occurring at evolutionarily conserved residues, was analysed by the MutPred tool whereas their potential effect on splicing was ascertained using the Skippy algorithm and a neural network. Although MutPred predicted that all 7 novel missense mutations would be likely to be deleterious, in silico analysis indicated that four of them (p.Leu146Val, p.Leu159Pro, p.Thr230Ile, p.Ala247Asp) might cause exon skipping by altering exonic splicing elements. These predictions were then investigated in vitro for both p.Leu146Val and p.Thr230Ile by means of RNA or minigene studies and were subsequently confirmed in the case of p.Leu146Val. Peripheral neuropathy was noted in four patients harbouring intragenic mutations that altered RNA processing, but was absent from all PLP1-duplication patients. Unprecedentedly, family studies revealed the de novo occurrence of the PLP1 duplication at a frequency of 20%.
- 1 March 2011
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 88 (3) , 392-393
Neurodegenerative Disorder Related to AIMP1/p43 Mutation Is Not a PMLD
- 1 March 2011
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 88 (3) , 392-393
Neurodegenerative Disorder Related to AIMP1/p43 Mutation Is Not a PMLD
- 15 May 2009
- Published by Elsevier in NeuroImage
- Vol. 46 (1) , 1-9
Characterisation of spinal cord in a mouse model of spastic paraplegia related to abnormal axono–myelin interactions by in vivo quantitative MRI
- 15 May 2009
- Published by Elsevier in NeuroImage
- Vol. 46 (1) , 1-9
Characterisation of spinal cord in a mouse model of spastic paraplegia related to abnormal axono–myelin interactions by in vivo quantitative MRI